This puts alcohol in roughly the same category as blood pressure medication, office air, Las Vegas and hairspray: We know they're bad for dry eye, but depending on your personal definition of quality of life, you may not really care.
Financial disclosures appended to studies like this crack me up. What possible conflict of interest could they have in this case? detox center? Seagram stock?
PURPOSE: To investigate whether ethanol administration disturbs the
tear film and ocular surface. DESIGN: Case-control study. PARTICIPANTS: Twenty healthy male subjects were recruited. Ethanol was
administered to 10 subjects and another 10 subjects served as controls. METHODS: Twenty healthy male subjects with no ocular disease
were recruited. Ethanol (0.75 g/kg) was administered orally at 8 pm for 2 hours
to 10 subjects. MAIN OUTCOME MEASURES: The tear film and ocular surface were evaluated at
6 pm before drinking, at midnight, and immediately (6 am) and 2 hours (8 am)
after waking the next morning. Tear osmolarity, ethanol concentration in tears
and serum, Schirmer's test results, tear film break-up time (TBUT), corneal
punctuate erosion, and corneal sensitivity were measured. RESULTS:
Ethanol was detected in tears and serum at midnight, but it
was not detected the next morning. The mean tear osmolarity level increased in
the alcohol group at midnight compared with that in the control group
(P<0.001). The alcohol group showed a significantly shorter TBUT compared
with the control group after drinking alcohol (P<0.001 at 12 am, P<0.001
at 6 am, and P = 0.002 at 8 am). There were significantly higher fluorescein
staining scores in the alcohol group compared with those in the control group
at 6 am and 8 am (P = 0.001 and P<0.001, respectively). No significant
change was shown in corneal sensitivity or Schirmer's test results in either
Orally administered ethanol was secreted into the tears.
Ethanol in tears induced tear hyperosmolarity and shortened TBUT and triggered
the development of ocular surface diseases. Similar changes could
exacerbate signs and symptoms in patients with ocular surface
disease. FINANCIAL DISCLOSURE(S):
The author(s) have no proprietary or commercial interest in
any materials discussed in this article.